James Trager - Nkarta Chief Officer
| NKTX Stock | USD 2.59 0.14 5.71% |
Insider
James Trager is Chief Officer of Nkarta Inc
| Age | 61 |
| Address | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 925 407 1049 |
| Web | https://www.nkartatx.com |
Latest Insider Transactions
James Trager Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Trager against Nkarta stock is an integral part of due diligence when investing in Nkarta. James Trager insider activity provides valuable insight into whether Nkarta is net buyers or sellers over its current business cycle. Note, Nkarta insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nkarta'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Trager over a year ago Exercise or conversion by James Trager of 2250 shares of NkartaInc subject to Rule 16b-3 |
Nkarta Management Efficiency
The company has return on total asset (ROA) of (0.1696) % which means that it has lost $0.1696 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.304) %, meaning that it created substantial loss on money invested by shareholders. Nkarta's management efficiency ratios could be used to measure how well Nkarta manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, Nkarta's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 132.1 M in 2024, whereas Total Assets are likely to drop slightly above 278.9 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan MS | Eliem Therapeutics | N/A | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| MD BA | Lumos Pharma | 69 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Richard Hawkins | Lumos Pharma | 75 | |
| BBA CPA | Lumos Pharma | 57 | |
| Hing Wong | HCW Biologics | 70 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Jeff York | Seres Therapeutics | N/A | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| David MBA | Seres Therapeutics | 63 | |
| Carl Langren | Lumos Pharma | 69 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| James JD | Eliem Therapeutics | 58 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Lori CPA | Lumos Pharma | 40 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.17 |
Nkarta Inc Leadership Team
Elected by the shareholders, the Nkarta's board of directors comprises two types of representatives: Nkarta inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nkarta. The board's role is to monitor Nkarta's management team and ensure that shareholders' interests are well served. Nkarta's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nkarta's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Hastings, President CEO | ||
| Ralph Brandenberger, Chief Officer | ||
| Nadir Mahmood, Chief Officer | ||
| Greg Mann, Vice Relations | ||
| Yvonne MBA, Chief Officer | ||
| Alicia Hager, Chief Secretary | ||
| James Trager, Chief Officer | ||
| David MD, Chief Development |
Nkarta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nkarta a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (24.71 M) | ||||
| Shares Outstanding | 70.57 M | ||||
| Shares Owned By Insiders | 4.86 % | ||||
| Shares Owned By Institutions | 98.82 % | ||||
| Number Of Shares Shorted | 9.57 M | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 1,000,000 X | ||||
| Gross Profit | (36.22 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Nkarta Stock Analysis
When running Nkarta's price analysis, check to measure Nkarta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nkarta is operating at the current time. Most of Nkarta's value examination focuses on studying past and present price action to predict the probability of Nkarta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nkarta's price. Additionally, you may evaluate how the addition of Nkarta to your portfolios can decrease your overall portfolio volatility.